Manufacturing

Feliza Mirasol is the science editor for 

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

Articles

Part 2—Industry experts from MilliporeSigma, Lonza, Astrea Bioseparations, and Sartorius provide insight and examples about solving critical challenges in both analytics and process development for emerging therapies.

Advances in Molecule Characterization and Biomanufacturing for Emerging Therapies: Part 2

Part 1—Industry experts from MilliporeSigma, Lonza, Astrea Bioseparations, and Sartorius discuss key issues affecting the development of emerging biotherapies.

Advances in Molecule Characterization and Biomanufacturing for Emerging Therapies: Part 1 

The research collaboration between Sartorius and Matica Biotechnology will aim to optimize PAT technologies, automation software, and single-use platforms for large-scale viral vector production.

Sartorius Forms Joint Research Pact with Matica Bio for Advanced Viral Vector Manufacturing Technology

The $691 million deal will see Vertex use Mammoth’s systems to discover and develop in-vivo gene-editing therapies.

Vertex and Mammoth Enter into Gene-Editing Partnership Worth Up to $691 Million

Jennifer Markarian is manufacturing reporter for Pharmaceutical Technology.

A new GMP facility in Raleigh, NC, and a starting materials facility in Paris, France, give Cellectis end-to-end, in-house manufacturing capacity for its UCART product candidates.  

Cellectis Opens GMP Manufacturing Facility

In this collaboration, Takeda will utilize Poseida's biodegradable DNA and RNA nanoparticle delivery technology and other proprietary genetic engineering platforms for the research and development of gene therapies.

Poseida Therapeutics and Takeda Partner to Develop Non-Viral In-Vivo Gene Therapy Programs

MilliporeSigma announced the opening of its second Carlsbad, California-based facility, which doubles production capacity to support commercial and industrial manufacturing of viral vectors. 

MilliporeSigma Completes $110-Million Contract Development Manufacturing Facility for Gene Therapy

The collaboration between Intellia and SparingVision will work to develop genomic medicines for ocular diseases.

Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology

Avid Bioservices is building a viral vector development and manufacturing facility near its existing biologics manufacturing facility in California. 

Avid Bioservices Expands into Viral Vector Development and Manufacturing Services

Pfizer may pay up to $630 million for access to Voyager’s novel AAV capsids in transgene research.

Manufacturing, Gene Therapies